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Field trials are extremely important for all facets of
research, breeding, and biotechnology. Tree physiology
is distinctively different in greenhouses or growth cham-
bers vs. field environments. Thus, results from non-field
environments can be very misleading with respect to
identification of promising biotechnologies and elite
varieties. Large regulatory impediments to conduct of
field tests of genetically modified (GM) trees will there-
fore tend to stifle scientific and technological develop-
ment. This appears to be the case for genetically
modified trees, where regulatory burdens to conducting
field tests have grown in stringency in the USA and
elsewhere in recent years [1,2]. Here, we present the
record of recent field trials and some new regulatory
developments in the USA.
Overview of field trials in the USA
Information Systems for Biotechnology (ISB) [3] main-
tains an easily used database of GM crop data in the
United States. There have been nearly 600 field trials
(including both “acknowledgments” and “permits”) con-
ducted since 1989, with a five-fold increase occurring in
2000-2009 compared with 1990-1999 (Figure 1).
Fifteen different genera have been tested, including
Populus, Pinus, Eucalyptus, and Malus, with the first
two accounting for approximately 60% of all field trials
(Figure 2). Marker genes and tolerance to biotic stresses
were the two most common research objectives. Private
companies carried out 60% of field trials, and their
activity has grown dominant in recent years.
Currently, there are more than sixty field trials cover-
ing eleven different genera, with Populus accounting for
35% of all field trials. Eucalyptus, Liquidambar, and
Malus together account for another 37% of trials. Other
genera being tested include Castanea (American chest-
nut), Pinus, Ulmus (American elm), Prunus, Musa,
Citrus, and Juglans. Forty field trials are being con-
ducted by private companies, with ArborGen alone
accounting for 36 of the 40 active field trials. Cornell
University, North Carolina State University, Oregon
State University, Purdue University, the United States
Department of Agriculture (ARS) and the University of
California, Davis are among the public institutions cur-
rently conducting field trials. One of ArborGen’s field
trials with cold tolerant Eucalyptus covers 197.2 acres.
This is the largest current field trial in terms of acres
and is being conducted in six different states. In terms
of research objectives of current trials, marker genes
dominate in terms of frequency of trials, with modifica-
tion of wood quality the next most common objective.
Regulation of field trials in the USA
In the USA, transgenic trees are regulated in the same
manner as agricultural crops [4], using regulatory laws
created prior to the development of transgenic biotech-
nology. The three agencies involved are the United
States Department of Agriculture (USDA), which con-
siders agricultural safety and economics; the Food and
Drug Administration (FDA), which considers human
and animal feed safety; and the Environmental Protec-
tion Agency (EPA), which considers pesticidal properties
of transgenic organisms [5]. Regulations in the United
States are perceived to be less stringent than those in
Europe and Asia, however, a recent survey in the USA
found that forest scientists—including breeders, biotech-
nologists, and ecologists—see regulations as major
obstacles to field research and commercial development
of GM trees [6].
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Recent regulatory developments
A company known as Okanagan Specialty Fruits has
taken the lead in the production of transgenic tree vari-
eties produced by the insertion of cisgenes and intra-
genes [7]. Non-browning versions of established apple
varieties were developed by the company by the silen-
cing of the polyphenol oxidase gene. These apples have
been named ArcticTM apples because of the color of
their skin. The company has petitioned the Animal and
Plant Health Inspection Service (APHIS) for deregula-
tion of the product in the USA [8].
Cold tolerant eucalyptus varieties were developed by
ArborGen [9]. The company believes that these varieties
would permit the planting of highly productive eucalypt
hybrids for bioenergy and pup north of Florida in the
USA. In May 2010, the USDA authorized a large scale
flowering field trial of these trees, thus permitting the
planting of nearly 260,000 trees over ~300 acres in
Figure 1 Total number of field trials with transgenic trees in the USA between 1990 and 2009.
Figure 2 Major genera of transgenic trees in field trials in the USA, 1990 to present.
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7 states [10]. However, several environmental organiza-
tions filed a lawsuit against APHIS because they believed
that APHIS performed an inadequate environmental
analysis, thus violating the US National Environmental
Policy Act (NEPA).
A new two year pilot project has recently been
announced by APHIS [11]. Under the provisions of the
new project—whose aim is to speed up the review pro-
cess before deregulation of biotech crops—environmen-
tal assessments of transgenic crops will be conducted by
companies themselves, or by contractors authorized by
the USDA. Although USDA would still need to review
and approve the analyses, critics of the new policy
believe that it might lead to less stringent environmental
analyses.
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